Save time and jump to the most important pieces.
4 - Bright Green Corp (0001886799) (Issuer)
4 - Bright Green Corp (0001886799) (Issuer)
4/A - Bright Green Corp (0001886799) (Issuer)
SC 13D/A - Bright Green Corp (0001886799) (Subject)
SC 13D - Bright Green Corp (0001886799) (Subject)
SC 13G/A - Bright Green Corp (0001886799) (Subject)
10-Q - Bright Green Corp (0001886799) (Filer)
8-K - Bright Green Corp (0001886799) (Filer)
NT 10-Q - Bright Green Corp (0001886799) (Filer)
GRANTS, NEW MEXICO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company"), today announced that trading of its shares have been suspended from the Nasdaq Stock Exchange ("Nasdaq") after Nasdaq cancelled the scheduled September 26, 2024 delist appeal hearing. While this development represents a change in the Company's public trading status, Bright Green remains committed to pursuing its strategic goals and delivering value to its shareholders. The Company filed its Proxy Statement and will proceed with its scheduled annual meeting on November 15, 2024, during which shareholders will discuss key issues, including the potential for a reve
GRANTS, NEW MEXICO, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use. This completely homegrown agreement signals Bright Green's ability and commitment to supply US pharmaceutical partners with high quality organic materials. As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Gr
GRANTS, NEW MEXICO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or the "Company") today announced that it has signed a letter of intent to supply its DEA-approved marijuana extracts and plant-based psychedelics to Benuvia Operations, a FDA registered, DEA licensed and cGMP certified leader in pharmaceutical cannabinoids, as well as psychedelic molecules currently under investigation for clinical use. This completely homegrown agreement signals Bright Green's ability and commitment to supply US pharmaceutical partners with high quality organic materials. As part of the supply agreement proposed in the LOI, Benuvia intends to leverage Bright Gree
Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently
Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently
Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval. Commencement of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan. Company has raised short-term working Capital of $5.26m to commence its operations as it looks to capitalize on its historic DEA Registration in Q2 2023 and beyond. GRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Brig
https://patentcenter.uspto.gov/applications/18213409/ifw/docs
Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. The company's market cap stands at $3.4 billion. Molecular Partners (NASDAQ:MOLN) shares moved upwards by 18.43% to $5.91. The market value of their outstanding shares is at $196.1 million. Longeveron (NASDAQ:LGVN) shares increased by 15.84% to $0.95. The company's market cap stands at $6.0 million. TRACON Pharma (NASDAQ:TCON) shares increased by 15.74% to $1.25. The market value of their outstanding shares is at $3.3 million. Oramed Pharmaceuticals (NASDAQ:ORMP) stock moved upwards by 14.49% to $2.37. The market value of their outstanding shares is at $96.2 million. NovaBay Pharm
Shares of GameStop Corp. (NYSE:GME) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to sell up to 75 million shares. GameStop released its first-quarter 2024 results early Friday ahead of its scheduled June 11 date. The company reported net sales of $881.8 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.3 million. The company reported a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share, according to data from Benzinga Pro. GameStop shares dipped 22.5% to $36.07 on Friday. Here are some other stocks moving in today